isupartob sodium

Isupartob sodium is a first-in-class, investigational heparin-derived histone binder being developed by Matisse Pharmaceuticals for the treatment of sepsis. It is a sodium salt of a specific heparin fraction characterized by low anticoagulant activity, obtained through affinity chromatography. The drug's mechanism of action involves binding to positively charged extracellular histones that are released into the bloodstream during sepsis. These histones are highly toxic and trigger a cascade leading to endothelial damage, organ failure, and death. By sequestering these proteins, isupartob sodium inhibits this self-enforcing pathological cycle. As of late 2025, the compound has completed Phase 1 trials in healthy volunteers and sepsis patients and has progressed into Phase 2 clinical development.

Other names

isupartob sodium